MTE #34: Molecular Regulation of Hepatic Stellate Cell Activation During Liver Injury and Fibrosis (Ticketed)

Nov 08 2026
Convention Center: Room 1F
12:45 PM - 1:30 PM
Ticketed event Ticketed Event
CE Credits CE Credits

Description

In this interactive session, experts discuss recent advances in hepatic stellate cell (HSC) biology in the context of liver injury and fibrosis progression. Quiescent HSCs play a critical role in liver homeostasis whereas activated HSCs are associated with fibrogenesis. Studies have identified distinct HSC populations that play differential roles during liver injury, tissue homeostasis, and fibrosis. Experts discuss the latest research on HSC functional heterogeneity, crosstalk with other liver cell types, and unique signaling pathways that influence HSC function during injury and fibrosis. The discussion focuses on recent advances in liver fibrogenesis, highlighting the spatial heterogeneity of HSCs and their distinct functional roles at the single-cell level, with an emphasis on the protective and disease-promoting roles of HSCs. Presenters review the molecular mechanisms underlying the dysregulation of regenerative pathways during sustained chronic liver injury with a specific focus on the roles of the ductular reaction and liver progenitor cells in HSC activation and fibrosis progression. Faculty also discuss recent advances in the mechanisms of HSC activation with a specific focus on novel molecular targets and therapeutic strategies to inactivate HSCs for the treatment of patients with liver fibrosis. The session provides attendees an excellent opportunity to engage in informal discussions with experts in the field and to gain valuable insights.  

Objectives

  • Outline the basic molecular mechanisms underlying liver fibrosis.
  • Describe the functional and spatial heterogeneity of hepatic stellate cells (HSCs) in liver tissue homeostasis and fibrogenesis, including the roles of the ductular reaction and liver progenitor cells in the progression of liver regeneration.
  • Review the molecular regulators of HSC activation and novel therapeutic targets for developing targeted therapies to manage liver fibrosis progression.